[RESEARCH BLOG] · 2026-09-25
Hims & Hers Health, Inc. (NYSE:HIMS) – BUY Signal Amid Recovery Regime and Strong Growth‑Compounder Profile
By Pierre Brunelle · Founder & Research Lead
Lede: Hims & Hers Health, Inc. (HIMS) closed at $29.42, up 0.48 % on 2026‑09‑25, as the LOPJLB model generated a BUY directional signal with a perfect Score 5 while the broader market entered a short‑term RECOVERY regime.
News Cluster
An insider transaction surfaced on 2026‑09‑25: Oluyemi Okupe, a senior executive at Hims & Hers, sold 29,277 shares of the company, according to a filing reported by DefenseWorld link. The sale represented a modest portion of the insider’s holdings and was disclosed in a routine Form 4 filing, suggesting no immediate material impact on the company’s capital structure.
The same filing noted that the shares were sold at an average price of $28.90, marginally below the market close of $29.42 on the filing date. While insider sales can sometimes be interpreted as a lack of confidence, the modest discount to market price and the absence of any accompanying commentary from management temper any negative inference.
No other corporate announcements, product launches, or regulatory updates were released in the same 24‑hour window, leaving the recent insider sale as the primary market‑moving news item for HIMS.
Fundamentals and Valuation
Hims & Hers Health has traversed a volatile earnings trajectory over the past six years, moving from a loss‑making startup to a company that posted positive earnings per share (EPS) and free cash flow (FCF) in 2024 and 2025. Revenue has compounded at an impressive ~70 % CAGR from $148.8 M in 2020 to $2.35 B in 2025, reflecting both organic growth in its tele‑health platform and successful expansion of its prescription‑drug portfolio.
Revenue Growth and Profitability
- 2020: $148.8 M revenue; EPS –$0.51; net margin –12.18 %
- 2021: $271.9 M revenue (+83 % YoY); EPS –$0.58; net margin –39.60 %
- 2022: $527.0 M revenue (+94 % YoY); EPS –$0.32; net margin –12.46 %
- 2023: $872.0 M revenue (+66 % YoY); EPS –$0.11; net margin –2.70 % (FCF turned positive at $46.99 M)
- 2024: $1.48 B revenue (+70 % YoY); EPS $0.58; net margin 8.54 % (FCF $198.33 M)
- 2025: $2.35 B revenue (+59 % YoY); EPS $0.57; net margin 5.47 % (FCF $73.96 M)
The shift from negative to positive EPS in 2024 marked the first full year of profitability, driven by higher-margin prescription renewals and improved operational efficiency. Gross margins have remained robust, hovering above 73 % since 2020 and peaking at 81.99 % in 2023, underscoring the scalability of the digital‑health model. Operating margins, however, have been more volatile, swinging from deep negatives in 2021 (‑42.31 %) to modest positives in 2024 (4.19 %) and 2025 (4.50 %). The recent dip in net margin to 5.47 % in 2025 reflects higher marketing spend as the firm seeks to capture additional market share in the burgeoning tele‑dermatology and wellness segments.
Balance‑Sheet Strength
The company carries a debt‑to‑equity ratio of 477.1, indicating a capital structure heavily weighted toward equity financing and limited leverage. This high D/E ratio is largely a function of the company’s growth‑stage financing rather than traditional debt, and it aligns with the industry norm for fast‑growing digital health platforms.
Valuation Multiples
Current valuation metrics are mixed, reflecting both the lingering perception of risk and the upside potential of a now‑profitable business:
| Metric | Value |
|---|---|
| P/E (TTM) | –48.23 |
| Forward P/E | 111.6 |
| P/B | 21.04 |
| EV/EBITDA | –98.14 |
| PEG | 2.67 |
| ROIC | –18.02 % |
| ROE | –30.03 % |
| ROA | –3.91 % |
| Gross Margin | 64.68 % |
| Operating Margin | –3.59 % |
| Net Margin | –5.51 % |
The negative trailing P/E reflects the residual impact of the 2023 loss year, while the forward P/E of 111.6 incorporates the recent earnings turnaround. The PEG ratio of 2.67 suggests that the stock is priced at a premium relative to its growth rate, but the premium is not extreme given the high growth trajectory. The price‑to‑book of 21.04 underscores the market’s expectation that intangible assets—primarily the proprietary tele‑health platform and brand equity—drive future earnings.
Analyst consensus remains Hold, with an average target price of $32.17, implying a modest upside of roughly 9.5 % from the current close. The consensus reflects a cautious optimism that the company can sustain its margin expansion while navigating competitive pressures from both traditional pharmacy chains and emerging digital‑health entrants.
ETF Ownership
Hims & Hers Health is held by a concentrated set of thematic and healthcare‑focused exchange‑traded funds, which together account for a notable portion of the float. The top twelve ETF holders collectively own ~30 % of the outstanding shares, a concentration that can amplify price movements on fund rebalancing activity.
| ETF Ticker | Weight % |
|---|---|
| EDOC | 5.74 % |
| THNR | 4.58 % |
| HEAL | 3.86 % |
| FDHT | 2.60 % |
| IBUY | 2.48 % |
| EKG | 2.34 % |
| XHS | 1.75 % |
| PTH | 1.60 % |
| BUZZ | 1.47 % |
| RFG | 1.03 % |
| IHF | 0.89 % |
| LGHT | 0.58 % |
The EDOC (First Trust Indxx NextGen Healthcare ETF) and THNR (VanEck Vectors Healthcare Innovation ETF) are the two largest holders, each representing a strategic bet on next‑generation health‑care business models. Their sizable stakes mean that any shift in the ETFs’ sector allocations—whether driven by macro‑level risk‑off moves or sector rotation—could influence HIMS’s share price more than a typical mid‑cap stock with a dispersed ownership base.
Market Pulse
The broader market environment as of 2026‑09‑25 is characterized by a RECOVERY regime on the 10‑day horizon, following a brief pullback that saw the EMA‑5 cross below EMA‑20. The market breadth indicator shows a 34 % bullish participation, while the technical overlay notes a stochastic K of 71.5, suggesting that momentum remains on the upside side of the neutral zone. Although the EMA crossover signals a short‑term bearish tilt, the overall regime classification as RECOVERY indicates that the market is regaining lost ground after a recent dip.
For HIMS, the % from high metric sits at ‑53.10 %, meaning the stock is trading just over half a percentage point below its 52‑week peak. This deep discount relative to its own historical high, combined with the recovery regime, aligns with the LOPJLB model’s BUY orientation.
LOPJLB Signal Read
The LOPJLB engine flags Hims & Hers Health with a BUY directional signal, operating within a RECOVERY market regime. The composite PERF score of 10.20 and FUND quality score of 28.10 place the stock in the upper‑mid tier of the model’s ranking system. The breakdown of the style scores—Value 5.00, Growth 34.00, GARP 28.00, Quality 28.10—identifies the company as a Growth Compounder archetype, meaning it exhibits strong earnings growth potential while maintaining improving profitability margins.
Investors can explore the full overlay of technical and quantitative signals on the interactive chart above this article. For a deeper dive into the methodology that drives the LOPJLB scores, consult the LOPJLB methodology page.
Closing Thoughts and Calls to Action
Hims & Hers Health has demonstrated a clear trajectory from loss‑making startup to a profitable digital‑health platform, with revenue scaling at a rapid pace and margins trending toward sustainable levels. The BUY signal from LOPJLB, set against a recovering market backdrop and reinforced by a concentrated ETF ownership base, provides a compelling data‑driven narrative for market participants who track quantitative signals.
For the most up‑to‑date price chart, detailed valuation tables, and the full suite of LOPJLB overlays, visit the dedicated stock page: https://www.lopjlb.com/stock/HIMS.
If you wish to review any earnings‑call commentary (should it become available) or explore historical earnings transcripts, see the earnings hub at https://www.lopjlb.com/stock/HIMS/earnings.md.
To screen for other high‑scoring opportunities across sectors, use the LOPJLB screener at https://www.lopjlb.com/screener.
All content herein is for informational and research purposes only and does not constitute investment advice. Readers should conduct their own due diligence and consider their individual risk tolerance before making any investment decisions.
This post is independent quantitative research, not investment advice. LOPJLB signals are model outputs derived from price, volume, and fundamentals. Past backtests do not guarantee future results. Position sizing, execution, and risk management remain the reader's responsibility.